SCLEROSTIN

PreclinicalBiologic

MMedical University of Lublin

SCLEROSTIN is one of 3 biologic programs targeting Mastocytosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

MastocytosisActive, not recruiting

MastocytosisPreclinical

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Mastocytosis

#DrugCompanyPhaseTrials

Rydapt

Plaquenil

SCLEROSTIN

MMedical University of Lublin

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Recruiting

Mastocytosis

NCT06440148

Clinical

Trials by Indication[1]

Mastocytosis1 trial

Relationship Between Circulating Sclerostin and Bone Lesions in Patients With Mastocytosis

Recruiting·MMedical University of Lublin··NCT06440148·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for SCLEROSTIN. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SCLEROSTIN compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SCLEROSTIN. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Medical University of Lublin company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: MMedical University of Lublin

SCLEROSTIN

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Mastocytosis1 trial

References

Drug Info

Quick Facts

Related News